FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

X 10% Owner

Other (specify below)

7. Nature of

Indirect Beneficial Ownership

(Instr. 4)

See

Footnote⁽²⁾

11. Nature

of Indirect

Beneficial

Ownership

(Instr. 4)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person Form filed by More than One Reporting

6. Ownership

Form: Direct

(I) (Instr. 4)

(D) or Indirect

Ι

10.

Form: Direct (D) or Indirect (I) (Instr. 4)

Ownership

Director

5. Amount of

Owned Following

20,674,424

9. Number of

derivative Securities

Owned

Following

Reported Transaction(s) (Instr. 4)

Beneficially

(Instr. 3 and 4)

Beneficially

Officer (give title

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 n 30(h) of the Investment Company Act of 1940

					or S	Section	1 30(h)	of the	Investn	nent C	ompany Act o	of 1940					
1. Name and Address of Reporting Person* PERCEPTIVE ADVISORS LLC					2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS INC [FOLD]									5. Relationship o (Check all applic Director			
(Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 09/21/2018								Officer (below)			
,					- 4. If	Amen	dmen	. Date	of Oriai	nal Fil	ed (Month/Da	v/Year)		6. Inc	dividual o	r J	
(Street)				4. If Amendment, Date of Original Filed (Month/Day/Year)									Line)				
NEW YORK NY 10003												Form fil X Form fil Person					
(City)	(St		Zip)	lon Doris	, cotive		ri+i			4 D	onesed o	f or D	onofic	المنا	, Own	=	
4 Tid			e i - iv			_			3.	u, D	sposed o			lally	5. Amou		
1. Title of Security (Instr. 3)				Date (Month/Day/Year)		Exec if any	A. Deemed execution Date, any Month/Day/Year)		Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar					ies iall Fo	
									Code	v	Amount	(A) or (D)	Price	Tran		tio	
Common	Stock			09/21/2018					P		50,000	A	\$12.5	2.53 ⁽¹⁾ 20,6		74	
		Та	ble II								osed of, o				Owned		
1. Title of	2.	3. Transaction	3A. De		4.		5. No	ımber			cisable and	7. Title	and		Price of	9.	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	if any	tion Date, n/Day/Year)	Transa Code (8)		Secu Acqu (A) o Disp of (D	erivative ccurities cquired) or sposed				ies /ing ive	Derivative Security (Instr. 5)		di Si Bi O Fi Ri (li		
						<u> </u>	and							4		(
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares				
		Reporting Person* ADVISORS L	<u>LC</u>				1.7	1.7									
(Last) 51 ASTC	OR PLACE,	(First) 10TH FLOOR	(N	1iddle)													
(Street)						-											
NEW YO	ORK	NY	10	0003													
(City) (State) (Zip)																	
	PTIVE L	Reporting Person* LIFE SCIENC	ES M	<u>IASTEI</u>	<u>2</u>												
(Last) (First) (Mir C/O PERCEPTIVE ADVISORS LLC 51 ASTOR PLACE, 10TH FLOOR			1iddle)														
,	, KILACE,	TOTTLELOOK				_											
(Street) NEW YO	ORK	NY	10	0003													
(City) (State) (Zip)			ip)														
	nd Address of	Reporting Person*															
(Last)	CEPTIVE	(First) ADVISORS LL	,	1iddle)													

51 ASTOR PLACE, 10TH FLOOR						
(Street) NEW YORK	NY	10003				
(City)	(State)	(Zip)				

Explanation of Responses:

- 1. The transaction was executed in multiple trades at prices ranging from \$12.31 to \$12.74. The price above reflects the weighted average price. Detailed information regarding the number of shares transacted at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
- 2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Remarks:

/s/ Perceptive Life Sciences

Master Fund Ltd., By:
Perceptive Advisors LLC, its investment manager By:
Joseph Edelman, its managing member
/s/ Perceptive Advisors LLC,
By: Joseph Edelman, its
managing member

09/25/2018

<u>/s/ Joseph Edelman</u> 09/25/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.